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Introduction
When cancer is diagnosed in the breast or colon with no evidence 
of distant spread, the tumor is removed, the patient is given adjuvant 
therapy if there is sufficient concern for relapse, and then the patient 
is  monitored  for  signs  of  metastatic  relapse  for  a  number  of  years 
thereafter. In the case of breast cancer such adjuvant therapy is hormone 
modulation if the primary tumor expresses estrogen or progesterone 
receptors  or  chemotherapy  if  it  does  not.  There  are  no  equivalent 
hormone receptors in colon cancer so therapy in that disease is always 
chemotherapy. The period of risk of relapse after therapy is of the order 
of 15-20 years in the case of breast cancer and 6-8 years for colon cancer.
Adjuvant chemotherapy is given approximately twice a month at 
or near maximum tolerated dosages and repeated when the patient’s 
immune system recovers sufficiently. This is conducted for six or so 
months in order to decrease the probability that there will be a metastatic 
relapse - that is incurable and the common pathway to eventual demise 
from the disease. The underlying reason why chemotherapy is used that 
way is the belief that tumor growth is fastest when it is small and then 
gradually slows as the tumor gets larger. Therefore, since chemotherapy 
interferes with cell division, the best way to treat early stage cancer while 
minimizing collateral damage to normal cells is to do it intensively and 
to start as soon as possible after primary surgery. The theory is not much 
more complicated than that [1-5]. When these theories are discussed, 
the mathematical equation that is commonly cited to describe tumor 
growth is the damped exponential called Gompertzian. If you follow 
the chain of experimental evidence cited that tumors actually grow in a 
Gomptertzian manner, you always arrive at the 1960s papers by Laird 
[6,7].
In the US in 2008 41,000 persons died from breast cancer and 
50,000 from colon cancer, most having had chemotherapy, so there 
is ample room for improvement. Something called drug resistance is 
blamed for eventual failure of chemotherapy. However, there is no clear 
molecular explanation why chemotherapy (or radiation for that matter) 
selectively kills tumor cells and why it ultimately fails [8].
I had been studying tumor growth since 1982 having made a career 
change from experimental physics to cancer biology. A person with 
my background is usually skilled in computational analysis and has 
much experience dealing with complex problems often with conflicting 
evidence. Those skills and that knowledge came in handy in November 
1994 when, after a routine physical exam, I was diagnosed with stage 
IIIc  colon  cancer.  There  were  4  nodes  positive  and  the  (sigmoid) 
primary tumor had penetrated the muscularis propria and into the 
pericolonic fat. In the tumor, p53 was mutated and the tumor cells were 
aneuploid. After checking relevant papers I determined that my risk of 
metastatic relapse was 80% without any chemotherapy and about 50% 
with chemotherapy.
The primary tumor was removed (anastomosis) and recovery was 
uneventful. After speaking with a few medical oncologists, I decided 
against the standard six months of intensive adjuvant chemotherapy and 
instead opted for a low dose non toxic daily course using the commonly 
used drug 5-fluorouracil (5FU). The duration was not specified at the 
time but I ultimately stayed on this therapy for 2.5 years. This therapy 
that I chose as adjuvant therapy had been used occasionally in late stage 
disease but never before in early stage as I intended to use it.
Bear in mind that I am not a gambler. I have lived in Connecticut 
for over 20 years and have never gone to the casinos that are only an 
hour away. I purchased one lottery ticket in my life and that was for 
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Abstract
This is a personal case history from a researcher who was studying tumor growth when diagnosed in 1994 with 
stage IIIc colon cancer. The risk of relapse was 80% without therapy and 50% with conventional therapy. However 
his previous research led him to challenge the idea that tumor growth was described by the Gompertz equation. This 
is the fundamental theory underlying the concept that adjuvant chemotherapy should be started as soon as possible 
after primary surgery and should be administered at maximum tolerated dose and repeated when the patient’s 
immune system recovers from the last course of therapy. It turns out that Gompertz growth is based on a study by 
Laird in the 1960s that consisted of measuring tumor growth on 18 rodents and one rabbit. On the basis of those 
data and a fundamental mathematical error, Laird claimed “The pattern of growth defined by the Gompertz equation 
appears to be a general biological characteristic of tumor growth.”  But then if the Gompertz equation assumption is 
wrong, how should adjuvant therapy be given? Patient/researcher opted for a low dose long term continuous infusion 
therapy with the mainstay colon cancer drug 5-flourouracil.  This therapy had previously been used in late stage 
disease but never in early stage disease. Patient used this non-toxic therapy 6 hours a night for 2.5 years. Patient 
was on the staff of Judah Folkman and after discussing this with Folkman, oncologist-researcher Tim Browder tested 
low dose long term continuous infusion 5- fluorouracil to determine if it is antiangiogenic. It was found to be so. This 
therapy is now called metronomic chemotherapy and is slowly being tested in laboratory, clinical and veterinary 
situations. Patient/researcher remains disease free 17 years later and asks why it is taking so long to proceed.
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a gag gift. What did I know in 1994 that so strongly convinced me to 
avoid the standard therapy for a life-threatening disease and instead 
take a different course that no one to my knowledge had ever used? In 
this paper I will discuss some of the evidence for Gompertzian kinetics, 
why I did not use short course and intensive adjuvant chemotherapy, 
and how this became known as metronomic chemotherapy.
Discussion
Gompertz was a 19th century actuarial scientist who proposed his 
equation as a general description of population growth. This growth 
starts exponentially (constant doubling time) and gradually slows down 
until it ultimately reaches a limiting plateau, as shown in Figure 1.
This is related to the Malthusian concept that the population of a 
city or state is ultimately limited by its food supply and ability to dispose 
of waste. Gompertzian growth is continuous, i.e., it cannot grow, stop, 
and then grow again. As mentioned, Gompertzian kinetics has played 
an important historical role in cancer chemotherapy and is still often 
cited. According to this theory, at the time of diagnosis of primary 
breast or colon cancer, metastatic disease is as small as it ever will be 
in the clinical setting—thus growing as fast and as chemosensitive as 
possible. Therefore, the optimal strategy for adjuvant chemotherapy 
is to use very intensive therapy as soon as possible after surgery for 
about 6 months and then hope for the best. This idea is traceable to the 
experimental work of Laird and by Skipper and Schabel in the 1960s 
and early 1970s [9-12]. 
Laird  measured  growth  of  “19  examples  of  12  different  tumors 
of the rat, mouse, and rabbit” and concluded: “The pattern of growth 
defined by the Gompertz equation appears to be a general biological 
characteristic of tumor growth.” That is a far reaching statement based 
on only 18 rodents and one rabbit!
Laird compared a Gompertzian equation that was fit to growth data 
for each of the 19 animals. Then Laird graphed the exponential equation 
that has the same value and slope as the Gompertzian at time equal zero. 
As no surprise, the pure exponential curve was accurate at t = 0 but 
rapidly became far larger than the best fit Gompertzian. That was not 
a fair test to determine if Gompertzian kinetics or exponential kinetics 
best fit these data. This flawed analysis was conducted for each of the 
19 tumors Laird reported. So in addition to using only 19 individual 
animals Laird used a flawed method to compare Gompertzian growth 
and exponential growth. Remarkably, Gompertzian kinetics as a valid 
description of breast cancer growth has been virtually unchallenged 
other than from my own publications starting in 1993 [13]. Laird papers 
have been cited over 600 times. Despite that, I came to the conclusion 
that I was the only person who actually read these papers and critically 
examined Laird’s data. The main drawback in its use to design clinical 
 
Figure 1: Gompertzian growth shown as log tumor burden (as represented by 
number of cells) vs. time (days). The equation is N = exp [(A/α ) * (1-exp[- α t])]. 
At small time the equation is exponential (tA) and at large time, the expression 
approaches the asymptotic value of exp (A/α). The Gompertzian growth model 
has long been assumed to describe primary and metastatic tumors. The growth 
starts as exponential (constant doubling time) which would appear as a straight 
line  on  this  semi-log  scale. There  are  two  parameters  in  this  function  that 
determine the initial growth rate and the ultimate size (N is the number of cells 
in the tumor). In figure 1, A was chosen as 0.3 per day and α was chosen to 
be 0.008 per day. Time t is expressed in days. The ultimate size asymptotically 
attainable in this example is 1.9 × 1016 cells. This value must be larger than 1012 
cells, the value that is usually taken as a lethal tumor burden, since untreated 
cancer is presumed to be uniformly lethal. Thus, the two parameters A and α 
are not completely independent. Exp (At) is equal to exp [(A/α ) * (1-exp[- α t]) 
at t = 0 but is larger at all other times greater than zero. 
Figure 2: As modified from Laird [7], for one particular tumor Laird fit W=W0 
*  exp  [(0.788/0.142)  *  (1–  exp  (-0.142  t))].  That  Gompertzian  expression 
reasonably well fit those data. Then expanding [1 –exp (-0.142 t)] in a Taylor 
series as [1 – 1 + 0.142 t –0.1422 t2/2! + …] or 0.142 t (arbitrarily taking only the 
first non-zero term), Laird concluded that the exponential curve to compare to 
the best fit Gompertzian fit is exp [0.788 t]. It is no surprise that the exponential 
starts at the same point as the Gompertzian but thereafter is always larger. This 
is a mathematical identity and has nothing to do with cancer.
Figure 3: From Squartini [23] as modified. These are spontaneous tumors 
in animals that are genetically prone to cancer. That is, tumor cells are not 
injected nor are carcinogenic agents used to induce cancer. Horizontal scale as 
indicated is 12 weeks. Vertical scale as indicated is 3 cm diameter.Volume 3(4): i-iv (2011) - iii 
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treatments stems from the unsupported belief that it was explanatory 
of “all” the natural history of tumors in the subclinical phase and the 
clinical phase. It is also true that since a tumor consists of more than 
just cancer cells, the size of a tumor may not be an accurate measure of 
how many cancer cells are contained within.
Skipper and Schabel’s work was done using multipassaged animal 
models with 1 or 2 day doubling times. They could cure animals if and 
only if all cancer cells were eradicated. Their papers included terms 
such as LD50 and LD90 to indicate that some of their chemotherapy 
protocols were lethally toxic to 50% or 90% of animals. The high success 
of using chemotherapy at maximum tolerate dose to treat animal model 
tumors has translated into only modest benefit in clinical breast and 
colon  cancer  and  accompanied  by  significant  toxicity.  Skipper  and 
Schabel  considered  human  tumor  growth  to  be  Gompertzian  and 
cited Laird as evidence. Their recommended method of treatment was 
to start as soon as possible using maximum tolerated doses repeated 
as soon as the host’s immune system recovered sufficiently from the 
previous treatment. The Skipper and Schabel papers have been cited 
over 2000 times and were very influential in oncology.
Additional information available to me before being diagnosed with 
colon cancer are data I published in 1990 [14]. I was Visiting Professor 
at University of Texas Health Science Center at Dr. William McGuire’s 
invitation. I was working on a method to include hormone receptors 
into a computer simulation of breast cancer that I developed previously. 
For about 6 months, I was spending alternate weeks in San Antonio 
while my family was living in Colorado Springs. In San Antonio, I was 
given a few columns from their 57,000 patient database but, as we found 
out months later, one of the columns provided to me was mislabeled. 
Instead of what I was told was “date of relapse” it was actually “date of 
last examination of patient”. As a result of the mislabeling, I could not 
make any progress for a number of months. Since my research was not 
getting anywhere, I had time to do other things and spent much time 
in their well stocked medical library. I was looking for serial data on 
tumor growth in untreated conditions. In the older literature “watchful 
waiting” was a common practice which is quite different from what 
happens today when a tumor is identified. 
The Briscoe Medical Library had an extensive collection of older 
journals. If I was reading one paper and saw some interesting references 
I could go to the stacks and examine all the referenced journals. This 
rarely  happens  in  libraries  when  researching  in  the  journals  from 
decades past. As a result I was able to identify over 100 examples of 
tumor  growth  in  animals  and  humans  that  showed  how  naturally 
occurring untreated tumors increased in size with time. I am quite 
competent in fitting algebraic functions to data but it would be sheer 
folly to try and come up with an equation that even resembles general 
tumor growth. Untreated tumors tend to increase in size over time but 
with no particular mathematically description that can remotely be 
said to cover more than a few tumors of the over 100 shown in Figure 
2 (As we now know tumor growth especially for breast cancer is very 
complicated [15]. One of the figures showing serial data on growth for 
30 spontaneous animal tumors from this 1990 paper is shown as Figure 
3.
By  1994  I  was  sure  that  there  was  a  big  difference  in  growth 
between multipassaged animal tumors as used by Laird and by Skipper 
and Schabel and spontaneous cancer and I especially questioned the 
reliance on Gompertzian kinetics to guide therapy.
When I was diagnosed at the end of October 1994, it can truly be 
said that I seriously doubted the dogma that adjuvant chemotherapy 
should be maximum tolerated dosage given intermittently for 6 months 
or so and then hope for the best. I was very dissolutioned with the 
science behind a therapy that had been and still is administered to a 
great many breast and colon cancer patients.
As mentioned, I used low dose long term therapy with the standard 
colon cancer drug for 2.5 years. It was administered for 6 hours per 
night using a portable pump through a double lumen port implanted 
on my chest under the skin. In the morning I disconnected the pump 
and flushed the thin plastic tubes. At bedtime I reprogrammed the 
pump and connected it back to the tubes. The original protocol was 
designed by medical oncologist Dr. William Hrushesky who had used 
this therapy on late stage patients but never before in early stage. (As 
originally designed, therapy was circadian rhythm timed but I gradually 
changed to a more convenient bedtime schedule.) The dosage chosen 
was 30% below the long term tolerable limit of 300 mg/m2/day and, 
since the toxicity profile is very steep, there was virtually no toxicity. 
I knew that I was getting the drug since there were small cracks in the 
skin at my finger joints, the finger tips were soft and somewhat numb 
and my fingernails grew coarsely. I had a few blood blisters inside my 
mouth. That was the full extent of the toxicity.
Over that period I did not miss a day of work, took no pain medicine, 
did not vomit and felt well enough to exercise vigorously daily. (I did 
not have much hair to start with so can’t say much about hair loss.) I was 
doing cancer research at Harvard Medical School during most of that 
period and on the staff of the late Judah Folkman. As many know, Dr. 
Folkman founded the field of tumor angiogenesis and was one of the 
most influential persons in the world in cancer research. He knew of my 
therapy and encouraged me to continue.
I was carefully monitored. In addition to the usual imaging studies, 
I had two conventional and two experimental tumor markers measured 
every month for over 5 years. There was one time when two of the 
markers temporarily rose slightly from a steady low level but never 
exceeded “normal” levels. Other than that, all markers were low and 
steady.
While in therapy, I discussed my treatment with Dr. Folkman. I 
knew that in the Folkman lab they were testing many compounds and 
substances for pro and antiangiogenic activity. I also knew from Dr. 
Hrushesky and other sources that low dose infusional 5FU apparently 
worked for extended periods of time seemingly without developing drug 
resistance. At that time the understanding was that an antiangiogenic 
therapy would not develop drug resistance. I therefore suspected that 
low dose infusional 5FU as I was using it might have antiangiogenic 
properties in addition to cytotoxic activity. I asked Dr. Folkman if they 
tested 5FU as bolus treatment as conventionally used or as long term low 
dose as I used it. Apparently it was only tested as bolus (high dose) and 
it was not antiangiogenic. Dr. Folkman then brought Dr. Tim Browder 
into the room. Browder was a pediatric medical oncologist and was the 
person conducting those measurements in the laboratory. It was clear 
that they had not tested it as I used it. Browder later purchased some 
micro implantable pumps and eventually tested 5FU and a number of 
other common cancer drugs at low dose for extended periods of time in 
mice and found that several of them including 5FU were antiangiogenic 
if administered that way. It took several years for Browder to get his 
findings published since they were totally unexpected. Finally they were 
published in 2000 [16]. 
I did not relapse and am now well beyond the period of risk of 
relapse for colon cancer so am 80% sure the therapy worked as planned 
for me.Volume 3(4): i-iv (2011) - iv 
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Conclusions
Robert Cooke happened to be writing an authorized biography of 
Judah Folkman and at Folkman’s direction interviewed me in 1999. 
By that time I was fairly confident the therapy worked. Either that or 
surgery was curative and the therapy was unnecessary. By that time, I 
had told many patients and physicians about low dose long term 5FU 
since Dr. Folkman directed them to me. I was also active as a patient-
advocate and a founder of the Colon Cancer Alliance. (I am still on 
the  Board  of  Directors.)  Cooke’s  biography  of  Judah  Folkman  was 
published in 2000 and there are three pages that discuss my medical 
history [17]. 
Unfortunately both Judah Folkman and Tim Browder are deceased. 
Dr. Folkman had introduced me on several occasions as the first human 
to use (adjuvant) metronomic chemotherapy – as this therapy is now 
known. The Browder et al paper has been cited over 600 times and 
metronomic chemotherapy has been tested many times especially in 
late stage disease. However I am sad to report that it is now 17 years 
since I used it and metronomic chemotherapy has still not been fully 
tested for use as originally designed in adjuvant treatment for early 
stage breast or colon cancer [18-21]. At this rate it could be another 
17 years before it is fully tested and then commonly used - assuming it 
works as well for others as it did for me. I had been unable to stimulate 
much interest in testing my therapy and a major reason is that 5FU 
is less expensive than sterile water. Who wants to spend a lot of time 
and money promoting a therapy when there is no financial benefit if 
it works? Maybe the research community can find an easier way to 
accomplish this with a different drug that is even more effective and 
that does not need to be infused over 6 hours daily. Perhaps Xeloda, the 
oral pro-drug for 5FU can be used instead. Hopefully my writing this 
paper will help speed the way toward the testing and usage of a non-
toxic low dose chemotherapy for early stage cancer. As a final comment, 
the elementary mathematical flaw in Laird’s papers and the fact that 
600 cancer researchers cited that study suggests that cancer researchers 
might consider additional training in basic mathematics.
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